Showing 4731-4740 of 5623 results for "".
- Sight Sciences Announces Positive Interim Results From Trial of the OMNI Surgical System in Open-Angle Glaucomahttps://modernod.com/news/sight-sciences-announces-positive-interim-results-from-trial-of-the-omni-surgical-system-in-open-angle-glaucoma/2478205/Sight Sciences announced positive 6-month interim safety and efficacy results from a prospective, multicenter, historically controlled clinical trial of the OMNI Surgical System in open-angle glaucoma (OAG). The OMNI Surgical System is currently cleared for use for the delivery of small amounts o
- FDA Approves Cystadrops for the Ocular Manifestations of Cystinosishttps://modernod.com/news/fda-approves-cystadrops-for-the-ocular-manifestations-of-cystinosis/2478201/Recordati Rare Diseases announced the FDA has approved Cystadrops (cysteamine ophthalmic solution 0.37%), a new, viscous eye drop solution that depletes corneal cystine crystal deposits in people living with cystinosis. Cystadrops demonstrated a significant reduction in cystine crystal deposits i
- SIFI Reports Positive Results From 044/si Phase 3 Clinical Trial of Netildex Gelhttps://modernod.com/news/sifi-reports-positive-results-from-044-si-phase-3-clinical-trial-of-netildex-gel/2478196/SIFI has announced the conclusion of a phase 3 clinical trial aimed at demonstrating the noninferiority of Netildex gel administered twice daily (BID) vs. Netildex solution administered four ti
- American Academy of Optometry Foundation Announces the 2020 Alfred A. Rosenbloom Jr. Low Vision Residency Award Recipienthttps://modernod.com/news/american-academy-of-optometry-foundation-announces-the-2020-alfred-a-rosenbloom-jr-low-vision-residency-award-recipient/2478194/The American Academy of Optometry has announced that Carolyn N. Chakuroff, OD, MS, is this year’s recipient of the Alfred A. Rosenbloom Jr. Low Vision Residency Award. Dr. Chakuroff is a graduate of The Ohio State University College of Optometry and an Ocular Disease/Low Vision Rehabilitation res
- Nanodropper Awarded a Phase 2 SBIR Contract With US Air Forcehttps://modernod.com/news/nanodropper-awarded-a-phase-2-sbir-contract-with-us-air-force/2478191/Nanodropper, the maker of an eyedrop bottle adaptor that reduces eyedrop size, has been named the recipient of a phase 2 Small Business Innovation Research (SBIR) contract with the United States Air Force. The Nanodropper adaptor was inspired by a 2017 ProPublica article detailing just how
- Fewer Side Effects Helped Spur Pfizer, BioNTech to Advance BNT162b2 Over Earlier COVID-19 Vaccine Candidatehttps://modernod.com/news/fewer-side-effects-helped-spur-pfizer-biontech-to-advance-bnt162b2-over-earlier-covid-19-vaccine-candidate/2478189/Pfizer and BioNTech released more details about why they recently selected their experimental coronavirus vaccine BNT162b2 over another candidate to advance into late-stage testing. According to a paper available on the medRxiv preprint server presenting additional phase 1 data from an ongoing US
- Kubota Vision Receives Orphan Products Clinical Trial Grant for Stargardt Disease Treatment Candidatehttps://modernod.com/news/kubota-vision-receives-orphan-products-clinical-trials-grants-to-emixustat-for-stargardt-disease/2478187/Kubota Vision announced that the FDA Office of Orphan Products Development (OOPD) has awarded an orphan products clinical trial grant to support the ongoing phase 3 study of emixustat in Stargardt disease. Orphan product clinical trial grants support well-controlled studies that will eithe
- WSJ: Troubled COVID-19 Data System Returning to CDChttps://modernod.com/news/wsj-troubled-covid-19-data-system-returning-to-cdc/2478184/The U.S. Department of Health and Human Services is reversing course on a change to the way hospitals report critical information on the coronavirus pandemic to the government, returning the responsibility for data collection to the Centers for Disease Control and Prevention, according to a W
- 4D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of 4D-125 for the Treatment of XLRPhttps://modernod.com/news/4d-molecular-therapeutics-announces-first-patient-dosed-in-phase-1-2-trial-of-4d-125-for-the-treatment-of-x-linked-retinitis-pigmentosa/2478179/4D Molecular Therapeutics (4DMT) announced that the first patient has been dosed in the phase 1/2 clinical trial of 4D-125 for X-linked retinitis pigmentosa (XLRP). 4D-125 is an AAV gene therapy with an optimized and proprietary vector designed to deliver a functional copy of the RPGR gene to pho
- Johnson & Johnson to Buy Momenta for $6.5 billionhttps://modernod.com/news/johnson-johnson-to-buy-momenta-for-6-5-billion/2478177/Johnson & Johnson entered into a definitive agreement to acquire Momenta Pharmaceuticals for $52.50 per share in cash, or approximately $6.5 billion, expanding its portfolio into autoantibody-driven autoimmune diseases. The transaction, which represents a premium of 70% to Momenta’s clo